scholarly journals Effects of sodium-glucose cotransporter 2 inhibitors on hypoglycaemia in brittle diabetic patients with decreased endogenous insulin secretion

2018 ◽  
Vol 2 (1) ◽  
pp. e00044
Author(s):  
Susumu Ogawa ◽  
Kazuhiro Nako ◽  
Sadayoshi Ito
Keyword(s):  
Insulin Secretion ◽  
Diabetic Patients ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Sodium Glucose Cotransporter

scholarly journals Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients

2010 ◽  
Vol 24 (4) ◽  
pp. 875-875
Author(s):  
Urd Kielgast ◽  
Meena Asmar ◽  
Sten Madsbad ◽  
Jens J. Holst
Keyword(s):  
Insulin Secretion ◽  
Cell Function ◽  
Glucagon Secretion ◽  
Diabetic Patients ◽  
Β Cell ◽  
C Peptide ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Type 1 Diabetic Patients

Abstract Context: The mechanism by which glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion is uncertain, and it is not determined whether endogenous insulin is a necessary factor for this effect. Objective: Our objective was to characterize the α- and β-cell responses to GLP-1 in type 1 diabetic patients without residual β-cell function. Methods: Nine type 1 diabetic patients, classified as C-peptide negative by a glucagon test, were clamped at plasma glucose of 20 mmol/liter for 90 min with arginine infusion at time 45 min and concomitant infusion of GLP-1 (1.2 pmol/kg · min) or saline. Results: Infusion with GLP-1 increased C-peptide concentration just above the detection limit of 33 pmol/liter in one patient, but C-peptide remained immeasurable in all other patients. In the eight remaining patients, total area under the curve of glucagon was significantly decreased with GLP-1 compared with saline: 485 ± 72 vs. 760 ± 97 pmol/liter · min (P < 0.001). In addition, GLP-1 decreased the arginine-stimulated glucagon release (incremental AUC of 103 ± 21 and 137 ± 16 pmol/liter · min, with GLP-1 and saline, respectively, P < 0.05). Conclusions: In type 1 diabetic patients without endogenous insulin secretion, GLP-1 decreases the glucagon secretion as well as the arginine-induced glucagon response during hyperglycemia. GLP-1 induced endogenous insulin secretion in one of nine type 1 diabetic patients previously classified as being without endogenous insulin secretion.

scholarly journals Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients

2010 ◽  
Vol 95 (5) ◽  
pp. 2492-2496 ◽  
Author(s):  
Urd Kielgast ◽  
Meena Asmar ◽  
Sten Madsbad ◽  
Jens J. Holst
Keyword(s):  
Insulin Secretion ◽  
Cell Function ◽  
Glucagon Secretion ◽  
Diabetic Patients ◽  
Β Cell ◽  
C Peptide ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Type 1 Diabetic Patients

Abstract Context: The mechanism by which glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion is uncertain, and it is not determined whether endogenous insulin is a necessary factor for this effect. Objective: To characterize the α- and β-cell responses to GLP-1 in type 1 diabetic patients without residual β-cell function. Methods: Nine type 1 diabetic patients, classified as C-peptide negative by a glucagon test, were clamped at plasma glucose of 20 mmol/liter for 90 min with arginine infusion at time 45 min and concomitant infusion of GLP-1 (1.2 pmol/kg · min) or saline. Results: Infusion with GLP-1 increased C-peptide concentration just above the detection limit of 33 pmol/liter in one patient, but C-peptide remained immeasurable in all other patients. In the eight remaining patients, total area under the curve of glucagon was significantly decreased with GLP-1 compared with saline: 485 ± 72 vs. 760 ± 97 pmol/liter · min (P < 0.001). In addition, GLP-1 decreased the arginine-stimulated glucagon release (incremental AUC of 103 ± 21 and 137 ± 16 pmol/liter · min, with GLP-1 and saline, respectively, P < 0.05). Conclusions: In type 1 diabetic patients without endogenous insulin secretion, GLP-1 decreases the glucagon secretion as well as the arginine-induced glucagon response during hyperglycemia. GLP-1 induced endogenous insulin secretion in one of nine type 1 diabetic patients previously classified as being without endogenous insulin secretion.

Endogenous insulin secretion in newly diagnosed diabetic patients in Saudi Arabia

1990 ◽  
Vol 8 (1) ◽  
pp. 51-59
Author(s):  
O.S. Al-Attas ◽  
M.A. Laajam ◽  
M.S. Khan ◽  
A.Z. Al-Dress
Keyword(s):  
Saudi Arabia ◽  
Insulin Secretion ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin

The addition of glipizide to insulin therapy in Type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion

1987 ◽  
Vol 116 (3) ◽  
pp. 364-372 ◽  
Author(s):  
Manuel Castillô ◽  
André J. Scheen ◽  
Giuseppe Paolisso ◽  
Pierre J. Lefébvre
Keyword(s):  
Insulin Secretion ◽  
Combined Therapy ◽  
Glucose Disposal ◽  
Diabetic Patients ◽  
Type Ii ◽  
Experimental Conditions ◽  
C Peptide ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Secondary Failure

Abstract. The present study aimed at 1) investigating the effect of a combined insulin + glipizide treatment on the metabolic control (HbA1c levels) and insulin requirements (Biostator® assessment) in ten non-obese Type-II diabetic patients with recent secondary failure to sulfonylureas; and 2) characterizing the relative contributions of changes in endogenous insulin secretion (C-peptide response) and insulin sensitivity (insulin-induced glucose disposal in clamped conditions) to this effect. The patients were treated in a randomized cross-over order with either insulin alone or insulin + glipizide (3 × 10 mg/day) during two periods averaging 6 weeks each. Mean HbA1c levels were similar in both experimental conditions (8.2 ± 0.6 vs 7.9 ± 0.6%, NS). In fact, during the combined therapy, HbA1c levels decreased in five subjects (from 8.6 ± 0.7 to 7.1 ± 0.5%; 'responders'), but not in the five others ('non-responders'); the 20-h Biostator insulin infusion was significantly decreased in the responders (29%; P < 0.05), but not in the non-responders. Basal (0.271 ± 0.086 vs 0.086 ± 0.017 nmol/l; P < 0.05) and post-glucagon (0.468 ± 0.121 vs 0.180 ± 0.060 nmol/l; P < 0.05) C-peptide plasma levels were significantly higher in the responders than in the non-responders; in addition, glipizide significantly increased basal C-peptide concentrations in the responders only (+ 68%; P < 0.05). The insulininduced glucose disposal was significantly increased by glipizide in the responders (+ 23%; P < 0.05), but not in the non-responders; however, this difference could be due to higher plasma free insulin levels (+ 37%; P < 0.02) during the clamp with glipizide in the responders who showed persistent C-peptide stimulation. Thus, combining glipizide with insulin seems to be useful only in Type-II diabetic patients who still have a significant endogenous insulin secretion capable of being stimulated by this compound.

scholarly journals Reduced endogenous insulin secretion in diabetic patients with low-titer positive antibodies against GAD

2012 ◽  
Vol 02 (01) ◽  
pp. 96-100 ◽  
Author(s):  
Yuichiro Takeuchi ◽  
Hiroyuki Ito ◽  
Koshiro Oshikiri ◽  
Shinichi Antoku ◽  
Mariko Abe ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Diabetic Patients ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin

Surrogate markers and predictors of endogenous insulin secretion in children and adolescents with type 1 diabetes

2021 ◽  
Author(s):  
Jin-Na Yuan ◽  
Jian-Wei Zhang ◽  
Wayne S. Cutfield ◽  
Guan-Ping Dong ◽  
You-Jun Jiang ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Secretion ◽  
Children And Adolescents ◽  
Surrogate Markers ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin

scholarly journals Glycated Albumin and Glycated Hemoglobin Are Influenced Differently by Endogenous Insulin Secretion in Patients With Type 2 Diabetes

Diabetes Care ◽  
2009 ◽  
Vol 33 (2) ◽  
pp. 270-272 ◽  
Author(s):  
M. Koga ◽  
J. Murai ◽  
H. Saito ◽  
S. Kasayama
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Secretion ◽  
Glycated Hemoglobin ◽  
Glycated Albumin ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin
Sign in / Sign up

Export Citation Format

Share Document